Using formalin-fixed paraffin-embedded tissue specimens, the authors studied the accumulation of p53 protein in various malignant bone tumors. p53 accumulation was detected in osteosarcoma (16.7%), malignant fibrous histiocytoma (MFH) of bone (30.4%), and chordoma (16.7%). In osteosarcoma, no difference was seen in the incidence of p53 accumulation according to the histologic grade of malignancy and any clinical factors including prognosis, but the incidence was significantly higher in conventional osteosarcoma than in other subtypes of osteosarcoma. In MFH of bone, the p53-positive group had a significantly worse prognosis compared with the p53-negative group. p53 accumulation is thus considered to be related to the prognosis of MFH of bone although it did not demonstrate any prognostic value for osteosarcoma in the current study.
1. Baker S, Markowitz S, Fearon ER, Willson JKV, Voglstein B. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science249:912-915, 1990
2.
2. Lavigueur A, Maltby V, Mock D, Rossant J, Pawson T, Bernstein A. High incidence of lung, bone, and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene. Mol Cell Biol9:3989-3991, 1989
3.
3. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee P. Mutations in the p53 gene occur in diverse human tumor types. Nature342:705-708, 1989
4.
4. Børresen A-L, Hovig E, Smith-Sorensen B, Malkin D, Lystad S, Andersen TI, Nesland JM, Isselbacher KJ, Friend SH. Constant denaturant gel electrophoresis as a rapid screening technique for p53 mutations. Proc Natl Acad Sci USA88:8405-8409, 1991
5.
5. Rodrigues NR, Rowan A, Smith ME, Kerr IB, Bodmer WF, Gannon JV, Lane DP. p53 mutations in colorectal cancer. Proc Natl Acad Sci USA87:7555-7559, 1990
6.
6. Lehman TA, Bennett WP, Metcalf RA, Welsh JA, Ecker J, Modali RV, Ullrich S, Romano JW, Appella E, Testa JR. p53 mutations, ras mutations, and p53-heat shock 70 protein complexes in human lung carcinoma cell lines. Cancer Res51:4090-4096, 1991
7.
7. Wadayama B, Toguchida J, Yamaguchi T, Ssaki MS, Kotoura Y, Yamamuro T. p53 expression and its relationship to DNA alterations in bone and soft tissue sarcomas. Br J Cancer68:1134-1139, 1993
8.
8. Rubio M-P, von Deimling A, Yandell DW, Wiestler OD, Gusella JF, Louis DN. Accumulation of wild type p53 protein in human astrocytomas. Cancer Res53:3465-3467, 1993
9.
9. Yew PR, Berk AJ. Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein. Nature357:82-84, 1992
10.
10. Hubbert NL, Sedman SA, Schiller JT. Human papillomavirus type 16 E6 increases the degradation rate of p53 in human keratinocytes. J Virol66:6237-6241, 1992
11.
11. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53 mediated transactivation. Cell69:1237-1245, 1992
12.
12. Hainaut P, Milner J. Interaction of heat-shock protein 70 with p53 translated in vitro: Evidence for interaction with dimeric p53 and for a role in the regulation of p53 conformation. EMBO J11:3513-3520, 1992
13.
13. Barnes DM, Dublin EA, Fisher CJ, Levison DA, Millis RR. Immunohistochemical detection of p53 in mammary carcinoma: An important new independent indicator of prognosis?Human Pathol24:469-476, 1993
14.
14. Thor AD, Moore DH II, Edgerton SM, Kawasaki ES, Reihsaus E, Lynch HT, Marcus JN, Schwartz L, Chen LC, Mayall BH. Accumulation of p53 tumor suppressor gene protein: An independent marker of prognosis in breast cancers. J Natl Cancer Inst84:845-855, 1992
15.
15. Isola J, Visakorpi T, Holli K, Kallioniemi OP. Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst84:1109-1114, 1992
16.
16. Martin H, Filipe MI, Morris R, Lane DP, Silverstre F. p53 expression and prognosis in gastric carcinoma. Int J Cancer50:1-4, 1992
17.
17. Kawai A, Noguchi M, Beppu Y, Yokoyama R, Mukai K, Hirohashi S, Inoue H, Fukuma H. Nuclear immunoreaction of p53 protein in soft tissue sarcomas: A possible prognostic factor. Cancer73:2499-2505, 1994
18.
18. Soini Y, Vahakangas K, Nuorva K, Kamel D, Lane DP, Paakko P. p53 immunohistochemistry in malignant fibrous histiocytomas and other mesenchymal tumors. J Pathol168:29-33, 1992
19.
19. Drobnjak M, Latres E, Pollack D, Karpeh M, Dudas M, Woodruff JM, Brennan MF, Cordon-Cardo C. Prognostic implications of p53 nuclear overexpression and high proliferative index of Ki-67 in adult soft tissue sarcomas. J Natl Cancer Inst86:549-554, 1994
20.
20. Dobashi Y, Sugimura H, Sato A, Hirabayashi T, Kanda H, Kitagawa T, Kawaguchi N, Imamura T, Machinami R. Possible association of p53 overexpression and mutation with high-grade chondrosarcoma. Diagn Mol Pathol2:257-263, 1993
21.
21. Broders AC, Hargrave R, Meyerding H. Pathologic reference to the grading of soft tissue fibrosarcoma. With special reference to the grading of its malignancy. Surg Gynecol Obstet69:267-280, 1939
22.
22. Oren M. p53: The ultimate suppressor gene?FASEB J6:3169-3176, 1992
23.
23. Lane DP, Benchimol S. p53: Oncogene or anti-oncogene?Genes Dev4:1-8, 1990
24.
24. Levine AJ, Momand J, Finlay CA. The p53 tumor suppressor gene. Nature351:453-456, 1991
25.
25. Berg FM, Tigges AJ, Schipper MEI, Hartog-Jager FCA, Kroes WGM, Walboomers JMM. Expression of the nuclear oncogene p53 in colon tumors. J Pathol157:193-199, 1989
26.
26. Purdie CA, O'Grady J, Piris J, Wyllie AH, Bird CC. p53 expression in colorectal tumors. Am J Pathol138:807-813, 1991
27.
27. Kawasaki Y, Monden T, Morimoto H, Murotani M, Miyoshi Y, Kobayashi T, Shimano T, Mori T. Immunohistochemical study of p53 expression in microwave-fixed, paraffin-embedded sections of colorectal carcinoma and adenoma. Am J Clin Pathol97:244-249, 1992
28.
28. Joypaul BV, Newman EL, Hopwood D, Grant A, Qureshi S, Lane DP, Cuschieri A. Expression of p53 protein in normal, dysplastic, and malignant gastric mucosa: An immunohistochemical study. J Pathol170:279-283, 1993
29.
29. Brito MJ, Williams GT, Thompson H, Filipe MI. Expression of p53 in early (TI) gastric carcinoma and precancerous adjacent mucosa. Gut35:1697-1700, 1994
30.
30. Brambilla E, Gazzeri S, Moro D, Fromentel CC, Gouyer V, Jacrot M, Brambilla C. Immunohistochemical study of p53 in human lung carcinomas. Am J Pathol143:199-210, 1993
31.
31. Ueda Y, Dockhorn-Dworniczak B, Blasius S, Mellin W, Wuisman P, Bocker W, Roessner A. Analysis of mutant p53 protein in osteosarcomas and other malignant and benign lesions of bone. J Cancer Res Clin Oncol119:172-178, 1993
32.
32. Oshiro Y, Fukuda T, Tsuneyoshi M. Fibrosarcoma versus fibromatoses and cellular nodular fasciitis. Am J Surg Pathol18:712-719, 1994
33.
33. Oshiro Y, Fukuda T, Tsuneyoshi M. Atypical fibroxanthoma versus benign and malignant fibrous histiocytoma: A comparative study of their proliferative activity using MIB-1, DNA flow cytometry, and p53 immunostaining. Cancer75:1128-1134, 1995
34.
34. Simms W, Ordnez NG, Johnston D, Ayala AG, Czerniak B. p53 expression in dedifferentiated chondrosarcoma. Cancer76:223-227, 1995
35.
35. McCormick D, Yu C, Hobbs C, Hall PA. The relevance of antibody concentration to the immunohistological quantitation of cell proliferation associated antigens. Histopathology22:543-548, 1993
36.
36. Esrig D, Spruck CH III, Nichols PW, Chaiwun B, Steven K, Groshen S, Chen SC, Skinner DG, Jones PA, Cote RJ. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol143:1389-1397, 1993
37.
37. Cattoretti G, Rilke F, Andreola S, D'Amato, Delia D. p53 expression in breast cancer. Int J Cancer41: 178-183, 1988
38.
38. Murakami Y, Hayashi K, Hirohashi S, Sekiya T. Aberration of tumor suppressor p53 and retinoblastoma genes in human hepatocellular carcinomas. Cancer Res51:5520-5525, 1991
39.
39. Furihata M, Inoue K, Ohtsuki Y, Hashimoto H, Terao N, Fujita Y. High-risk human papillomavirus infections and overexpression of p53 protein as prognostic indicators in transitional cell carcinoma of the urinary bladder. Cancer Res53:4823-4827, 1993
40.
40. Bosari S, Lee AKC, Viale G, Heatley GJ, Coggi G. Abnormal p53 immunoreactivity and prognosis in node-negative breast carcinomas with long-term follow-up. Virchows Archiv A Pathol Anat421:291-295, 1992
41.
41. Poller DN, Roberts EC, Bell JA, Elston CW, Blamey RW, Ellis IO. p53 protein expression in mammary ductal carcinoma in situ: Relationship to immunohistochemical expression of estrogen receptor and c-erbB-2 protein. Hum Pathol24:463-468, 1993
42.
42. Masuda H, Miller C, Koeffler H, Battifora H, Cline M. Rearrangement of the p53 gene in human osteogenic sarcomas. Proc Natl Acad Sci USA84:7716-7719, 1987
43.
43. Miller CW, Aslo A, Tsay C, Slamon D, Ishizaki K, Toguchida J, Yamamuro T, Lampkin B, Koeffler HP. Frequency and structure of p53 rearrangements in human osteosarcoma. Cancer Res50:7950-7954, 1990
44.
44. Mulligan LM, Matlashewski GJ, Scrable HJ, Cavenee WK. Mechanisms of p53 loss in human sarcomas. Proc Natl Acad Sci USA87:5863-5867, 1990
45.
45. Stratton MR, Moss S, Warren W, Patterson H, Clark J, Fisher C, Fletcher CD, Ball A, Thomas M, Gusterson BA. Mutation of the p53 gene in human soft tissue sarcomas: Association with abnormalities of the RB1 gene. Oncogene5:1297-1301, 1990
46.
46. Toguchida J, Yamaguchi T, Ritchie B, Beauchamp RL, Dayton SH, Herrera GE, Yamamuro T, Kotoura Y, Sasaki MS, Little JB. Mutation spectrum of the p53 gene in bone and soft tissue sarcomas. Cancer Res52:6194-6199, 1992
47.
47. Andreassen Å, Øyjord T, Hovig E, Holm R, Flørenes VA, Nesland JM, Myklebost O, Hoie J, Bruland OS, Borrensen AL. p53 abnormalities in different subtypes of human sarcomas. Cancer Res53:468-471, 1993
48.
48. Cordon-Cardo C, Latres E, Drobnjak M, Oliva MR, Pllack D, Woodruff JM, Marechal V, Chen J, Brennan MF, Levine AJ. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res54:794-799, 1994
49.
49. Flørenes VA, Mælandsmo GM, Forus A, Andreassen Å, Myklebost Ola, Fodstad Ø. MDM2 gene amplification and transcript levels in human sarcomas: Relationship to TP53 gene status. J Natl Cancer Inst86:1297-1302, 1994
50.
50. Porter PL, Gown AM, Kramp SG, Coltrera D. Widespread p53 overexpression in human malignant tumors: An immunohistochemical study using methacarn-fixed, embedded tissue. Am J Pathol140:145-153, 1992
